Fact Source: Financial Supervisory Service DART / 2025-08-22
Disclosure Type: Amending Report / Material Facts Report (Decision on Corporate Split)
💡 3-Second Summary
Samsung Biologics has amended its corporate restructuring schedule, postponing the Extraordinary General Meeting of Shareholders to October 17, 2025, and adjusting the expected relisting date of the newly spun-off entity to November 24, 2025.
📊 1. [Key Disclosure Content & Summary of Financial Figures]
- Company Name: Samsung Biologics Co., Ltd. (207940)
- Restructuring Method: Simple spin-off / Inverted spin-off (Surviving entity: Samsung Biologics Co., Ltd. [CDMO Business Division], New entity: SAMSUNG EPIS HOLDINGS CO.,LTD. [Management of subsidiaries and new investments, etc.])
- Split Ratio: Surviving Entity 0.6503913 : New Entity 0.3496087 (Based on the book value of net assets as of March 31, 2025)
- Core Schedule Revisions (Postponement):
- Extraordinary General Meeting (EGM): [Pre-revision] 2025-09-16 → [Post-revision] 2025-10-17
- Split Date: [Pre-revision] 2025-10-01 → [Post-revision] 2025-11-01
- Trading Suspension Period: [Pre-revision] 2025-09-29 to 2025-10-28 → [Post-revision] 2025-10-30 to 2025-11-21
- Record Date for New Stock Allocation: [Pre-revision] 2025-09-30 → [Post-revision] 2025-10-31
- Expected Relisting Date for New Shares: [Pre-revision] 2025-10-29 → [Post-revision] 2025-11-24
- Pro Forma Financial Posture (As of March 31, 2025):
- Surviving Co.: Total Assets KRW 9,986,729,911,728, Total Liabilities KRW 3,743,013,838,765, Total Equity KRW 6,243,716,072,963
- New Co.: Total Assets KRW 3,365,179,974,094, Total Liabilities KRW 8,958,509,056, Total Equity KRW 3,356,221,465,038
- Future Plans & Material Terms:
- The new entity is reviewing the establishment of a new subsidiary to engage in bio-related new businesses between the split date and the relisting application date. Detailed plans including investment scale and business strategies will be disclosed once finalized.
- The new entity will ensure that its subsidiary, Samsung Bioepis Co., Ltd., will not list its shares on domestic or foreign stock exchanges for five years from the date of the incorporation registration.
- Appraisal rights and creditor protection procedures are not applicable due to the structure of the simple spin-off.
📈 2. [Expert Insight: What This Disclosure Means for Investors]
This filing operates strictly as an amendment report signaling a shift in the administrative and procedural timeline of the corporate split project, rather than representing structural modifications in the underlying business value or financial metrics. The essential parameters, including the split ratio of approximately 65:35 and the conceptual division into a specialized CDMO unit and a subsidiary management unit, remain consistent with the previous filing.
For market participants, it is necessary to verify the updated dates for the shareholder meeting, the trading suspension period, the record date, and the expected relisting date. Investors should reassess their upcoming procedural schedules based on these adjusted timelines. Furthermore, specific details regarding the company’s future restructuring plans, such as the potential establishment of a new subsidiary and the subsidiary non-listing clause, should be tracked through official subsequent disclosures to be released upon finalization.
📝 Editor’s Comment (by K-STOCK Editor)
The corporate split timeline for Samsung Biologics has officially been adjusted through this amending report! The key shareholder meeting is deferred to October 17, and the exchange’s trading suspension period and the relisting date have also shifted in tandem. Although the procedural execution schedule has been postponed, the structural framework of the split and the 65:35 breakdown remain fully intact as initially designed. Investors should review the revised dates carefully and monitor future verified filings regarding the shareholder vote and the new subsidiary plans to evaluate the upcoming execution phases.
📢 Disclaimer & Source Information
Source: This content has been structured and newly generated based on the official data submitted to the Financial Supervisory Service electronic disclosure system (DART).
Investment Risk Notice: This information is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific stock. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
🔥 Bulls vs Bears, drop your analysis in the comments!
